192 related articles for article (PubMed ID: 27579614)
21. Molecular features of adult glioma associated with patient race/ethnicity, age, and a polymorphism in O6-methylguanine-DNA-methyltransferase.
Wiencke JK; Aldape K; McMillan A; Wiemels J; Moghadassi M; Miike R; Kelsey KT; Patoka J; Long J; Wrensch M
Cancer Epidemiol Biomarkers Prev; 2005 Jul; 14(7):1774-83. PubMed ID: 16030116
[TBL] [Abstract][Full Text] [Related]
22. PI3 kinase mutations and mutational load as poor prognostic markers in diffuse glioma patients.
Draaisma K; Wijnenga MM; Weenink B; Gao Y; Smid M; Robe P; van den Bent MJ; French PJ
Acta Neuropathol Commun; 2015 Dec; 3():88. PubMed ID: 26699864
[TBL] [Abstract][Full Text] [Related]
23. PARP1 expression and its correlation with survival is tumour molecular subtype dependent in glioblastoma.
Murnyák B; Kouhsari MC; Hershkovitch R; Kálmán B; Marko-Varga G; Klekner Á; Hortobágyi T
Oncotarget; 2017 Jul; 8(28):46348-46362. PubMed ID: 28654422
[TBL] [Abstract][Full Text] [Related]
24. Immunohistochemical profiles of IDH1, MGMT and P53: practical significance for prognostication of patients with diffuse gliomas.
Ogura R; Tsukamoto Y; Natsumeda M; Isogawa M; Aoki H; Kobayashi T; Yoshida S; Okamoto K; Takahashi H; Fujii Y; Kakita A
Neuropathology; 2015 Aug; 35(4):324-35. PubMed ID: 25950388
[TBL] [Abstract][Full Text] [Related]
25. Pediatric glioblastomas: a histopathological and molecular genetic study.
Suri V; Das P; Pathak P; Jain A; Sharma MC; Borkar SA; Suri A; Gupta D; Sarkar C
Neuro Oncol; 2009 Jun; 11(3):274-80. PubMed ID: 18981259
[TBL] [Abstract][Full Text] [Related]
26. Epithelioid glioblastomas stratify into established diagnostic subsets upon integrated molecular analysis.
Korshunov A; Chavez L; Sharma T; Ryzhova M; Schrimpf D; Stichel D; Capper D; Sturm D; Kool M; Habel A; Kleinschmidt-DeMasters BK; Rosenblum M; Absalyamova O; Golanov A; Lichter P; Pfister SM; Jones DTW; Perry A; von Deimling A
Brain Pathol; 2018 Sep; 28(5):656-662. PubMed ID: 28990704
[TBL] [Abstract][Full Text] [Related]
27. Genetic, epigenetic, and molecular landscapes of multifocal and multicentric glioblastoma.
Liu Q; Liu Y; Li W; Wang X; Sawaya R; Lang FF; Yung WK; Chen K; Fuller GN; Zhang W
Acta Neuropathol; 2015 Oct; 130(4):587-97. PubMed ID: 26323991
[TBL] [Abstract][Full Text] [Related]
28. BRAF VE1 immunoreactivity patterns in epithelioid glioblastomas positive for BRAF V600E mutation.
Kleinschmidt-DeMasters BK; Aisner DL; Foreman NK
Am J Surg Pathol; 2015 Apr; 39(4):528-40. PubMed ID: 25581727
[TBL] [Abstract][Full Text] [Related]
29. Immunohistochemical expression of IDH1 in gliomas: a tissue microarray-based approach.
Sipayya V; Sharma I; Sharma KC; Singh A
J Cancer Res Ther; 2012; 8(4):598-601. PubMed ID: 23361281
[TBL] [Abstract][Full Text] [Related]
30. Distinct genomic profile and specific targeted drug responses in adult cerebellar glioblastoma.
Cho HJ; Zhao J; Jung SW; Ladewig E; Kong DS; Suh YL; Lee Y; Kim D; Ahn SH; Bordyuh M; Kang HJ; Sa JK; Seo YJ; Kim ST; Lim DH; Dho YS; Lee JI; Seol HJ; Choi JW; Park WY; Park CK; Rabadan R; Nam DH
Neuro Oncol; 2019 Jan; 21(1):47-58. PubMed ID: 30085274
[TBL] [Abstract][Full Text] [Related]
31. Nuclear Protein Phosphatase 1 α (PP1A) Expression is Associated with Poor Prognosis in p53 Expressing Glioblastomas.
Shastry AH; Thota B; Srividya MR; Arivazhagan A; Santosh V
Pathol Oncol Res; 2016 Apr; 22(2):287-92. PubMed ID: 26253838
[TBL] [Abstract][Full Text] [Related]
32. Epilysin is overexpressed in glioblastoma and related to clinical outcome of patients.
Wang X; Zhang K; Chen X; Zhao C; Sun Z
Med Oncol; 2015 Jan; 32(1):363. PubMed ID: 25429835
[TBL] [Abstract][Full Text] [Related]
33. Comprehensive analysis of Reverse Phase Protein Array data reveals characteristic unique proteomic signatures for glioblastoma subtypes.
Patil V; Mahalingam K
Gene; 2019 Feb; 685():85-95. PubMed ID: 30401645
[TBL] [Abstract][Full Text] [Related]
34. LOC283731 promoter hypermethylation prognosticates survival after radiochemotherapy in IDH1 wild-type glioblastoma patients.
Mock A; Geisenberger C; Orlik C; Warta R; Schwager C; Jungk C; Dutruel C; Geiselhart L; Weichenhan D; Zucknick M; Nied AK; Friauf S; Exner J; Capper D; Hartmann C; Lahrmann B; Grabe N; Debus J; von Deimling A; Popanda O; Plass C; Unterberg A; Abdollahi A; Schmezer P; Herold-Mende C
Int J Cancer; 2016 Jul; 139(2):424-32. PubMed ID: 26934681
[TBL] [Abstract][Full Text] [Related]
35. Glioblastoma: pathology, molecular mechanisms and markers.
Aldape K; Zadeh G; Mansouri S; Reifenberger G; von Deimling A
Acta Neuropathol; 2015 Jun; 129(6):829-48. PubMed ID: 25943888
[TBL] [Abstract][Full Text] [Related]
36. Comprehensive portrait of recurrent glioblastoma multiforme in molecular and clinical characteristics.
Li R; Chen X; You Y; Wang X; Liu Y; Hu Q; Yan W
Oncotarget; 2015 Oct; 6(31):30968-74. PubMed ID: 26427041
[TBL] [Abstract][Full Text] [Related]
37. Chemokine receptor CXCR7 is an independent prognostic biomarker in glioblastoma.
Deng L; Zheng W; Dong X; Liu J; Zhu C; Lu D; Zhang J; Song L; Wang Y; Deng D
Cancer Biomark; 2017 Jul; 20(1):1-6. PubMed ID: 28759950
[TBL] [Abstract][Full Text] [Related]
38. Farewell to GBM-O: Genomic and transcriptomic profiling of glioblastoma with oligodendroglioma component reveals distinct molecular subgroups.
Hinrichs BH; Newman S; Appin CL; Dunn W; Cooper L; Pauly R; Kowalski J; Rossi MR; Brat DJ
Acta Neuropathol Commun; 2016 Jan; 4():4. PubMed ID: 26757882
[TBL] [Abstract][Full Text] [Related]
39. Pathology: commonly monitored glioblastoma markers: EFGR, EGFRvIII, PTEN, and MGMT.
Camara-Quintana JQ; Nitta RT; Li G
Neurosurg Clin N Am; 2012 Apr; 23(2):237-46, viii. PubMed ID: 22440867
[TBL] [Abstract][Full Text] [Related]
40. Genomic landscape of gliosarcoma: distinguishing features and targetable alterations.
Zaki MM; Mashouf LA; Woodward E; Langat P; Gupta S; Dunn IF; Wen PY; Nahed BV; Bi WL
Sci Rep; 2021 Sep; 11(1):18009. PubMed ID: 34504233
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]